Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast

Rhea-AI Summary

Voyager Therapeutics, a biotechnology company, will report its Q3 2023 financial and operating results on November 6, 2023. A conference call and webcast will be held to review the results. Telephone participants can register in advance to receive a confirmation email with details on how to join the call. The webcast will be available on the Voyager website, and a replay will be available for at least 30 days.

CAMBRIDGE, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced it will report third quarter 2023 financial and operating results after market close on Monday, November 6, 2023. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET to review its financial and operating results.

To participate via telephone and join the call live, please register in advance here. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique passcode. A live webcast of the call will also be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com, and a replay of the call will be available at the same link approximately two hours after its completion. The replay will be available for at least 30 days following the conclusion of the call.

About Voyager Therapeutics
Voyager Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The potential of both disciplines has been constrained by delivery challenges; Voyager is leveraging cutting-edge expertise in capsid discovery and deep neuropharmacology capabilities to address these constraints. Voyager’s TRACER™ AAV capsid discovery platform has generated novel capsids with high target delivery and blood-brain barrier penetration at low doses, potentially addressing the narrow therapeutic window associated with conventional gene therapy delivery vectors. This platform is fueling alliances with Pfizer Inc., Novartis Pharma AG, Neurocrine Biosciences, Inc., and Sangamo Therapeutics, Inc., as well as multiple programs in Voyager’s own pipeline. Voyager’s pipeline includes wholly owned and collaborative preclinical programs in Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other diseases of the central nervous system, with a focus on validated targets and biomarkers to enable a path to rapid potential proof-of-biology. For more information, visit www.voyagertherapeutics.com.

Voyager Therapeutics^® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc. 

Contacts
Investors
Investors@vygr.com

Media
Peg Rusconi
prusconi@vergescientific.com

FAQ

When will Voyager Therapeutics report its Q3 2023 financial and operating results?

Voyager Therapeutics will report its Q3 2023 financial and operating results on November 6, 2023.

What will be discussed during the conference call and webcast?

The conference call and webcast will review Voyager Therapeutics' financial and operating results for Q3 2023.

How can I participate in the conference call?

To participate in the conference call, you can register in advance on the Voyager Therapeutics website and receive a confirmation email with details on how to join.

Where can I access the webcast?

The webcast will be available on the Investors section of the Voyager Therapeutics website at ir.voyagertherapeutics.com.

Will there be a replay of the conference call?

Yes, a replay of the conference call will be available on the Voyager Therapeutics website for at least 30 days after its completion.